Junshi Bio's Global First-in-Class Lymphodepletion- and IL-2-Free TIL Therapy GC101 Enters Clinical Trial at Peking University Cancer Hospital

The Department of Melanoma and Sarcoma Medical Oncology at Peking University Cancer Hospital isThe Largest in Asia, Internationally AuthoritativeCenter for the Treatment of Malignant Melanoma, alsoThe Leading Unit for the Compilation of the Chinese Guidelines for the Diagnosis and Treatment of Melanoma.The department has undertaken and led clinical research related to melanoma.More than 70 items, includingCFDA Registration Studies for All Melanoma Drugs, and have been successively approved5 unitsA new anti-tumor drug with epoch-making significance. In addition, multiple SCI papers have been incorporated into the NCCN guidelines for melanoma, renal cell carcinoma, and head and neck cancers in the United States, making significant contributions to the advancement of international diagnosis and treatment of melanoma.

GC101It is independently developed by Juncell Therapeutics.The World's FirstAn autologous natural TIL cell injection that requires no lymphodepletion and no IL-2 injection has been approved by the National Medical Products Administration (NMPA) to enter Phase I clinical trials in April 2022.The First Batch in China）。Compared with traditional TIL therapy,GC101 TIL Therapy Has 2 Significant Advantages:1）No lymphodepletion preconditioning required, no IL-2 injection at any dose required，Minimal restrictions on the physical condition of subjects；2) Can beReceive Treatment in General Ward，Simple Treatment Process。

Currently, multiple patients with advanced solid tumors of various cancer types have been treated with GC101 infusion, showing an overall objective response rate.Over 35% (Tumor reduction of 30% or more), among which3 casesPatientThe tumor was completely cleared.，The longest tumor-free survival time has exceeded 2 years.。All SubjectsNo SAEs related to GC101 occurred.(Severe Adverse Event),Good safety profile.

Lin

Bed

Recruitment

Recruit